Clinical trial · Interventional
Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
Study of Efficacy of PAD-regimen(Bortezomib,Pirarubicin and Dexamethasone) and TAD-regimen(Thalidomide,Pirarubicin and Dexamethasone) in Newly Diagnosed Multiple Myeloma,Influence in Concentration of Bone Metabolites,and the Relations With Different Cytogenetic and Molecular Biological Changes
NCT01249690CI-TRIAL-00004147unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary purpose of this study is to evaluate the efficacy of PAD-regimen and TAD-regimen in newly diagnosed multiple myeloma(MM).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bortezomib,Pirarubicin,Dexamethasone | Drug | — | UNRESOLVED |
| Thalidomide,Pirarubicin,Dexamethasone | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- PAD
- interventionNames
- Drug: Bortezomib,Pirarubicin,Dexamethasone
- type
- EXPERIMENTAL
- label
- TAD
- interventionNames
- Drug: Thalidomide,Pirarubicin,Dexamethasone
Primary outcomes (1)
- measure
- The overall response rate of PAD and TAD in patients with MM assessed by International Myeloma Working Group(IMWG) criteria
- timeFrame
- every treatment cycle
Secondary outcomes (4)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects with symptomatic and measurable newly diagnosed Multiple Myeloma. * Age \> 18 years, KPS ≥ 60, and life expectancy of at least 3 months. * Subjects must meet all of the following criteria within 14 days before starting therapy: PLT≥50×109/L, Hb≥70 g/L, ANC≥0.75×109/L * Subjects (or their legally acceptable representatives) must signed an informed consent document. Exclusion Criteria: * Severe cardiovascular disease ; HIV infection, or positive HBsAg, or active hepatitis C; HBV-DNA\>104; hepatic functional parameter\>2.5 times the upper limit of institutional laboratory normal. * Grade 2 or more severe peripheral neuropathy or neuropathic pain; Grade 2 or more severe impaired hepatic and kidney function. * Patient has radiotherapy or major surgery within 30 days before enrollment. * Patient has hypersensitivity to boron, mannitol or thalidomide. * Pregnant or breastfeeding women, or subject unwilling to use a method for contraception during the study.
References
Publications (0)
Data not yet available
No reference posted for this study.